FILTER BY:
Details
Testing the Addition of Immunotherapy Before Surgery for Patients with Sarcomatoid Mesothelioma
Address: 5700 S Maryland Ave, Chicago, IL 60637, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: False
- Peritoneal: False
- Pericardial: False
- Tunica Vaginalis: False
Type: Sarcomatoid, Biphasic
Condition: Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Description: This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.
Research Center: University of Chicago Medicine
Treatment Interventions: BIOLOGICAL: Nivolumab, BIOLOGICAL: Ipilimumab, PROCEDURE: Surgical Procedure, PROCEDURE: Computed Tomography, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Positron Emission Tomography
Potential Impact: High
Clinical Trial Number: NCT05647265
Phase: Phase 2
Status: Recruiting
